Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.52 Insider Own41.43% Shs Outstand9.40M Perf Week-8.97%
Market Cap26.70M Forward P/E- EPS next Y-0.89 Insider Trans0.00% Shs Float5.51M Perf Month-13.74%
Income-12.85M PEG- EPS next Q-0.27 Inst Own21.36% Short Float0.03% Perf Quarter-7.49%
Sales0.00M P/S- EPS this Y17.41% Inst Trans- Short Ratio0.12 Perf Half Y17.84%
Book/sh6.57 P/B0.43 EPS next Y20.18% ROA-16.86% Short Interest0.00M Perf Year11.81%
Cash/sh2.45 P/C1.16 EPS next 5Y- ROE-19.82% 52W Range1.72 - 3.59 Perf YTD-1.73%
Dividend Est.- P/FCF- EPS past 5Y47.80% ROI-20.82% 52W High-20.89% Beta1.55
Dividend TTM- Quick Ratio14.26 Sales past 5Y-20.00% Gross Margin- 52W Low65.12% ATR (14)0.17
Dividend Ex-Date- Current Ratio14.26 EPS Y/Y TTM73.40% Oper. Margin0.00% RSI (14)40.92 Volatility4.05% 7.10%
Employees4 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price9.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q91.39% Payout- Rel Volume0.83 Prev Close2.95
Sales Surprise- EPS Surprise51.43% Sales Q/Q- EarningsJun 21 BMO Avg Volume13.59K Price2.84
SMA20-5.87% SMA50-3.46% SMA2001.86% Trades Volume11,455 Change-3.84%
Date Action Analyst Rating Change Price Target Change
Sep-01-20Downgrade Oppenheimer Outperform → Perform
Jul-06-20Upgrade B. Riley FBR Neutral → Buy $2
Jan-13-20Downgrade B. Riley FBR Buy → Neutral
Aug-29-19Initiated B. Riley FBR Buy $7.75
Jul-18-19Initiated Oppenheimer Outperform $7
Jun-26-19Initiated H.C. Wainwright Buy $6
Jul-10-24 09:40AM
Jun-27-24 04:05PM
Jun-21-24 01:53PM
Jun-18-24 12:31PM
04:05PM Loading…
May-28-24 04:05PM
May-23-24 06:45AM
Mar-24-24 03:54PM
Feb-12-24 08:00AM
Feb-01-24 08:00AM
Dec-13-23 08:00AM
Nov-13-23 08:20AM
Oct-23-23 08:00AM
08:00AM Loading…
Oct-04-23 08:00AM
Sep-26-23 08:00AM
Sep-06-23 08:00AM
Aug-23-23 03:49AM
Aug-22-23 09:19AM
Aug-11-23 07:10AM
Aug-09-23 04:05PM
Jul-28-23 08:02AM
Jul-10-23 09:00AM
Jul-07-23 08:00AM
Jul-05-23 09:00AM
Jun-23-23 07:00AM
Jun-22-23 09:00AM
May-17-23 09:00AM
07:41AM Loading…
May-10-23 07:41AM
May-08-23 07:00AM
Apr-04-23 08:01AM
Mar-30-23 08:30AM
Mar-13-23 08:00AM
Mar-08-23 09:00AM
Mar-04-23 08:28AM
Feb-28-23 01:00PM
Feb-15-23 04:02PM
Feb-14-23 07:00AM
Feb-07-23 09:00AM
Jan-25-23 09:00AM
Jan-24-23 04:15PM
Jan-17-23 10:00AM
Jan-13-23 09:00AM
Jan-05-23 09:00AM
Dec-29-22 06:02AM
Dec-28-22 08:00AM
Dec-22-22 08:00AM
Nov-14-22 07:00AM
Nov-09-22 04:15PM
Nov-07-22 04:15PM
Sep-30-22 09:00AM
Sep-29-22 09:00AM
Sep-21-22 08:45AM
Sep-14-22 04:15PM
Sep-13-22 08:00AM
Sep-12-22 09:00AM
Aug-11-22 01:00PM
Aug-02-22 04:15PM
Jul-27-22 08:00AM
Jul-07-22 08:55AM
Jun-22-22 06:10PM
Jun-21-22 08:00AM
Jun-16-22 04:15PM
Jun-14-22 08:00AM
May-23-22 04:15PM
May-18-22 11:20AM
May-16-22 01:30PM
May-12-22 08:00AM
May-06-22 09:02AM
Apr-25-22 08:30AM
Mar-25-22 07:30AM
Mar-22-22 07:30AM
Mar-09-22 08:30AM
Feb-28-22 08:30AM
Feb-23-22 09:50AM
Feb-22-22 09:09AM
Feb-14-22 07:00AM
Feb-07-22 08:30AM
Jan-03-22 08:30AM
Dec-23-21 10:49AM
Dec-22-21 03:40PM
Dec-21-21 04:57AM
Dec-02-21 07:00AM
Nov-24-21 08:30AM
Nov-12-21 05:34PM
Nov-11-21 08:30AM
Nov-10-21 07:00AM
Nov-04-21 08:30AM
Oct-07-21 10:15AM
Oct-06-21 08:30AM
Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002, and is headquartered in Princeton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kavuru VimalDirectorSep 25 '23Buy1.85676,3711,249,9341,188,076Sep 27 07:46 PM
Olds DonaldDirectorAug 31 '23Buy2.05381781381Sep 05 03:54 PM